fluoxetine has been researched along with Disorders of Excessive Somnolence in 7 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Disorders of Excessive Somnolence: Disorders characterized by hypersomnolence during normal waking hours that may impair cognitive functioning. Subtypes include primary hypersomnia disorders (e.g., IDIOPATHIC HYPERSOMNOLENCE; NARCOLEPSY; and KLEINE-LEVIN SYNDROME) and secondary hypersomnia disorders where excessive somnolence can be attributed to a known cause (e.g., drug affect, MENTAL DISORDERS, and SLEEP APNEA SYNDROME). (From J Neurol Sci 1998 Jan 8;153(2):192-202; Thorpy, Principles and Practice of Sleep Medicine, 2nd ed, p320)
| Excerpt | Relevance | Reference |
|---|---|---|
| " This open-label study evaluated the efficacy and safety of modafinil treatment initiated with an SSRI in patients with MDD and fatigue." | 9.11 | Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. ( Glass, SJ; Hassman, HA; McManus, FC; Ninan, PT, 2004) |
| " This open-label study evaluated the efficacy and safety of modafinil treatment initiated with an SSRI in patients with MDD and fatigue." | 5.11 | Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. ( Glass, SJ; Hassman, HA; McManus, FC; Ninan, PT, 2004) |
| "The majority of recent papers in this field provide information about use of modafinil or sodium oxybate for treatment of sleepiness associated with narcolepsy." | 4.84 | Treatment of narcolepsy and other hypersomnias of central origin. ( Arand, DL; Auger, RR; Brooks, SN; Watson, NF; Wise, MS, 2007) |
| "Successful treatment of hypersomnia of central origin requires an accurate diagnosis, individual tailoring of therapy to produce the fullest possible return of normal function, and regular follow-up to monitor response to treatment." | 2.44 | Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. ( Alessi, C; Aurora, RN; Boehlecke, B; Brown, T; Chesson, AL; Friedman, L; Kapur, VK; Maganti, R; Morgenthaler, TI; Owens, J; Pancer, J; Swick, TJ; Zak, R, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ninan, PT | 1 |
| Hassman, HA | 1 |
| Glass, SJ | 1 |
| McManus, FC | 1 |
| Martenyi, F | 1 |
| Brown, EB | 1 |
| Caldwell, CD | 1 |
| Morgenthaler, TI | 1 |
| Kapur, VK | 1 |
| Brown, T | 1 |
| Swick, TJ | 1 |
| Alessi, C | 1 |
| Aurora, RN | 1 |
| Boehlecke, B | 1 |
| Chesson, AL | 1 |
| Friedman, L | 1 |
| Maganti, R | 1 |
| Owens, J | 1 |
| Pancer, J | 1 |
| Zak, R | 1 |
| Wise, MS | 1 |
| Arand, DL | 1 |
| Auger, RR | 1 |
| Brooks, SN | 1 |
| Watson, NF | 1 |
| Geracioti, TD | 1 |
| Loosen, PT | 1 |
| Gold, PW | 1 |
| Kling, MA | 1 |
| Sabalesky, DA | 1 |
2 reviews available for fluoxetine and Disorders of Excessive Somnolence
| Article | Year |
|---|---|
Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin.
Topics: Antidepressive Agents, Tricyclic; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants | 2007 |
Treatment of narcolepsy and other hypersomnias of central origin.
Topics: Antidepressive Agents, Tricyclic; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants | 2007 |
2 trials available for fluoxetine and Disorders of Excessive Somnolence
| Article | Year |
|---|---|
Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorde | 2004 |
Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study.
Topics: Adult; Antidepressive Agents, Second-Generation; Diagnostic and Statistical Manual of Mental Disorde | 2007 |
3 other studies available for fluoxetine and Disorders of Excessive Somnolence
| Article | Year |
|---|---|
Cortisol, thyroid hormone, and mood in atypical depression: a longitudinal case study.
Topics: Adult; Affect; Depressive Disorder; Disorders of Excessive Somnolence; Female; Fluoxetine; Humans; H | 1992 |
Additional cases of suicidal ideation associated with fluoxetine.
Topics: Adult; Depressive Disorder; Disorders of Excessive Somnolence; Female; Fluoxetine; Humans; Male; Sui | 1990 |
Fluoxetine in adults with residual attention deficit disorder and hypersomnolence.
Topics: Activities of Daily Living; Adult; Arousal; Attention Deficit Disorder with Hyperactivity; Depressiv | 1990 |